Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 16Terminated 7Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Hydroxychloroquine × Clear all
NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT05083780 2025-04-16

Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

Asan Medical Center

Phase 1 Active not recruiting
40 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡